制药提价与抑制仿制药方式 472条(本栏目收费,不能显示细节,电话13136136841)
Reckitt Benckiser (drug company) In re Suboxone case of, 87,90, 95,97 97
See also Generation 1.0 strategies; Generation 0
2.0 strategies; pay- for- delay; REMS (Risk 0
Evaluation and Mitigation Strategies) 0
Actelion case and, 82,83 83
boy scout contract clauses, 137 137
carve- out request for generic Abilify(antipsychotic, Otsuka), 110,112 112
carve- out request for generic Crestor(AstraZeneca), 108,110, 111,112 112
carve- out request for generic Skelaxin(King Pharmaceuticals), 105,108 108
Endo’s boy scout clause, 78,79 79
evergreening as obstruction strategy, 69 69
FDA acceptance of obstructionist petitions 0
filed by brands against generics, 69 69
generic substitution systems as obstruction mechanism, 66,67 67
product hopping by Actavis from Namenda to Namenda XR, 76,78 78
product hopping of AstraZeneca from Prilosec 0
product hopping of Warner Chilcott of Asacol to Delzicol, 74,76 76
product hopping steps, 69,71 71
profits from obstructionist strategies for delay, 67,69 69
skinny labels and carve- out requests and, 103,04 4
subversion of FDA safety guidelines as, 67 67
Big Pharma’s efforts to extend monopoly profits 0
by blocking entry of, 9 9
effect on pharmaceutical pricing and costs and, 20,21 21
Hatch- Waxman Act as new era for, 21, 33 33
loss of market share for brand name drug companies and, 7 7
restricted distribution system and pricing controversy over Darapim, 9,10 10
restricted distribution system and pricing increases for Thiola (Retrophin), 10,11 11